ArticleEBioMedicine2019
Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).
Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Case Report: Severe wound formation following intratumoral tigilanol tiglate treatment resulting in limb amputation in a 10-year-old male dog.Frontiers in veterinary science · 2026Article
- Targeting KIF20A: a new frontier in cancer treatment revealed by multi-omics analysis.Frontiers in immunology · 2026Article
- Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas.Equine veterinary journal · 2026Article
- Australian Rainforests-A Living Museum of Natural Product Chemical Diversity.Progress in the chemistry of organic natural products · 2025Review
- Article
- Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade.Journal for immunotherapy of cancer · 2024Article
- Immunogenic oncolysis by tigilanol tiglate.Oncoimmunology · 2024Article
- Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice.Journal for immunotherapy of cancer · 2023Article
- Tigliane and daphnane diterpenoids from Thymelaeaceae family: chemistry, biological activity, and potential in drug discovery.Journal of natural medicines · 2023Review
- DefiningJournal of oral microbiology · 2023Article
- Non-apoptotic cell death induction via sapogenin based supramolecular particles.Scientific reports · 2022Article
- Anti-HIV Tigliane-Type Diterpenoids from the Aerial Parts ofJournal of natural products · 2022Article
- Identification of Gene Biomarkers for Tigilanol Tiglate Content inMolecules (Basel, Switzerland) · 2022Article
- Acoustically Detonated Microbubbles Coupled with Low Frequency Insonation: Multiparameter Evaluation of Low Energy Mechanical Ablation.Bioconjugate chemistry · 2022Article
- Intratumoural administration and tumour tissue targeting of cancer immunotherapies.Nature reviews. Clinical oncology · 2021Review
- Floral attraction and flower visitors of a subcanopy, tropical rainforest tree,Ecology and evolution · 2021Article
- Article
- The P450 multigene family of Fontainea and insights into diterpenoid synthesis.BMC plant biology · 2021Article
- Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes.Scientific reports · 2021Article
- Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).Journal of veterinary internal medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTigilanol tiglate, a short-chain diterpene ester, is being developed as intratumoral treatment of a broad range of cancers. We conducted the first-in-human study of intratumoral tigilanol tiglate in patients with solid tumors.
methodsTigilanol tiglate was administered in a multicentre, non randomized, single-arm study, with escalating doses beginning with 0·06 mg/m
findingsTwenty-two patients were enrolled. The maximum dose was 3·6 mg/m
interpretationIntratumoral tigilanol tiglate was generally well tolerated, the maximum tolerated dose was not reached, and clinical activity was observed in 9 tumor types including complete response in four patients. These results support the continued development of tigilanol tiglate for intratumoral administration.
fundingQBiotics Group Limited Brisbane, Queensland, Australia was the sponsor of the study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.